BAXTER INTERNATIONAL INC
NYSE: BAX·Deerfield, Illinois·CIK 0000010456
- Price
- $25.54
- Base IV
- $27.71
Valuation snapshot
At $25.54, the price sits between our bear case ($7.01) and base case ($27.71).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $27.71
- above today's price · range $7.01–$50.56
- Price vs base case
- 8% below
- $25.54 against $27.71
- Base case · our researched forecast, 2026-11-01See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 8.7% since this valuation was struck on 2026-11-01, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $7.01 to bull $50.56. Values per share.
Price against each value
- Bear case
- $7.01
- Price 264% above
- No growth
- …
- —
- Base case
- $27.71
- Price 8% below
What does Baxter International do?
Baxter provides hospitals and healthcare facilities with intravenous solutions, infusion systems, surgical equipment, and pharmaceuticals to manage patient care and treatment.
It brought in $11.6B of sales in the 12 months to Sep 2026.
Led by Andrew Hider, President and Chief Executive Officer since 2025. Baxter International Inc. Form 8-K
- Industry
- Healthcare
- Based in
- Deerfield, Illinois
- Trades on
- NYSE as BAX
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.06, so it lost 6¢ on each dollar. The biggest cost is making what it sells, 70¢ of every dollar.
- Making what it sells70¢
- Research and development4¢
- Sales, marketing and admin25¢
- Everything else it takes to operate2¢
- Tax4¢
- Other items after tax1¢
- Lost on each dollar−6¢
Who pays Baxter International, and for what?
Baxter sells medical products and therapies, hospital equipment and monitoring systems, and injectable and inhaled medicines. It makes money by selling these products and related services to healthcare providers and patients in more than 100 countries.
Its customers include hospitals, clinics, care centers, distributors, governments, and patients using home therapies under medical supervision.
Medical Products & Therapies
47%Sterile IV solutions, infusion systems and supplies, nutrition therapies, and surgical products.
Baxter VIAFLO IV solution bagImage: Baxter International Healthcare Systems & Technologies
27%Connected care products, smart beds, patient monitors, respiratory devices, and surgical equipment.
Pharmaceuticals
22%Injectable medicines, inhaled anesthetics, and drug compounding services.
Other
3%Primarily transition and manufacturing services related to the sale of Kidney Care, plus contract manufacturing.
Where its work physically happens, beyond headquarters:
- North Cove plant — Marion, United States. This major IV solutions plant is critical to Baxter’s supply, and hurricane damage there disrupted production and affected financial results.
- Cleveland plant — Cleveland, United States. The plant produces IV containers and medication reconstitution devices, with Baxter reporting capacity of about 3.4 million units a day.
- Round Lake campus — Round Lake, United States. The campus manufactures pharmaceuticals and drug delivery products, making it an important production site for Baxter’s Pharmaceuticals segment.
- Guayama plant — Guayama, United States. The plant produces IV solutions and inhaled anesthesia products that support Baxter’s hospital and pharmaceutical supply.
- Alliston plant — Alliston, Canada. The plant manufactures IV fluids for Canadian patients and has also supplied the U.S. during an IV fluid shortage.
How is the business doing?
Sales have barely moved over 5 years, from $11.7B in 2020 to $11.2B in 2025.
It spends more to run the business than it brings in: an operating loss of 2¢ per sales dollar.
What does management say it's aiming for?
Baxter says its mission is to save and sustain lives.
“Save and Sustain Lives.”
Who is responsible for the plan?
- Andrew HiderPresident and Chief Executive Officer
He oversees Baxter's global operations, corporate strategy, and comprehensive portfolio of medical technologies and therapies. Baxter generates revenue by manufacturing and selling essential medical devices, intravenous products, pharmaceuticals, and connected care systems globally.
- Maria Cecilia SorianoGroup President, Infusion Therapies & Technologies and Pharmaceuticals
She oversees the operational, commercial, and product strategies for Baxter's Infusion Therapies & Technologies and Pharmaceuticals divisions. These product divisions make money through the production and sale of intravenous delivery sets, infusion pumps, clinical nutrition, and specialty injectable pharmaceuticals.
Roles checked November 14, 2026.
What management says it is working on now:
Stabilize the business
Management says it is working to improve supply reliability, strengthen execution, and build more consistent performance across the business.
Baxter International (BAX) Q2 2026 Earnings Call TranscriptStrengthen the balance sheet
Baxter says reducing debt remains its top near-term capital allocation priority, while it works toward its net leverage goal.
Baxter International (BAX) Q2 2026 Earnings Call TranscriptImprove performance
Management says it is using the Baxter Growth and Performance System to encourage continuous improvement and improve results.
Baxter Reports Second-Quarter 2026 ResultsGrow through innovation
The company says it is building connected care and core therapy offerings and prioritizing research and development where it sees opportunities to serve patients and providers.
Baxter International Inc. 2025 Form 10-KExpand margins
Management expects margins to improve in the second half of 2026, supported by higher seasonal volumes, cost actions, and the use of higher-cost inventory produced earlier.
Baxter International (BAX) Q2 2026 Earnings Call Transcript
- Adjusted diluted earnings per share, Full year 2026
- $1.95 to $2.15
- Baxter Reports Second-Quarter 2026 Results
- Adjusted operating margin, Full year 2026
- 13% to 14%
- Baxter International (BAX) Q2 2026 Earnings Call Transcript
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 5%.
Its operating margin is wider than a year ago: 8¢ per sales dollar, against 6¢.
Since Oct 2026 the share price has risen 9%, from $23.50 to $25.54.
Recently
September 30, 2026
Capital expenditure, first nine months changed to $363.0M
Baxter Q3 2026 Form 10-Q, cash flowsSeptember 30, 2026
Medical Products & Therapies sales, first nine months changed to $6.1B
Baxter Q3 2026 Form 10-Q, segment salesSeptember 30, 2026
Reported operating margin, third quarter changed to 7.6%
Baxter Q3 2026 Form 10-Q, income statement
Coming up
Timing uncertain; hold was in effect as of the 2025 annual report
Novum IQ pump correction and distribution hold
The timing for lifting the U.S. and Canadian shipment and installation hold remains uncertain. Baxter expects no meaningful Novum IQ large-volume pump sales while the hold is in effect.
Baxter International Inc. 2025 Form 10-KAfter the 2025 Corporate Responsibility Report; date not specified
2026 Corporate Responsibility goals
Baxter expects to announce refreshed corporate responsibility commitments and goals after publishing its 2025 report, either separately or as part of its 2026 report.
Baxter International Inc. 2025 Form 10-K
Our own estimate moved too: the base case went from $21.07 to $27.71 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Product safety and quality
Problems with product quality or manufacturing can lead to recalls, costs, and lost sales. Baxter's Novum IQ infusion pumps have had safety corrections, and U.S. and Canadian distribution and installation of the large-volume pump were paused pending further corrections.
From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K
Competition and pricing
Rivals compete on price, service, product performance, and innovation. Hospital purchasing groups and customer consolidation can increase discount demands and make it harder to raise prices.
From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K
Supply and manufacturing disruptions
Shortages or delays in materials, components, manufacturing, or delivery can limit sales and raise costs. Some inputs come from single-source suppliers, and replacement suppliers may take time to qualify.
From the company's own filingsWould hit how much of each sale it keepsBaxter International Inc. 2025 Form 10-K
Debt and financial flexibility
Baxter had about $9.48 billion of debt at the end of 2025. Repaying it uses cash that could otherwise support research, investment, or other business plans, and missing its debt goal could raise borrowing costs.
From the company's own filingsWould hit how much it has to reinvestBaxter International Inc. 2025 Form 10-K
Regulation and reimbursement
Many products need government approval before sale and remain subject to inspection and oversight. Changes to approval rules, healthcare payments, or pricing policies could delay launches, limit sales, or reduce revenue.
From the company's own filingsWould hit how fast sales growBaxter International Inc. 2025 Form 10-K
Tariffs and economic uncertainty
Baxter says tariffs and inflation have raised costs, while long-term customer contracts can limit how quickly it passes those costs on. Economic weakness may also lead customers to delay orders or reduce hospital spending.
From the company's own filingsWould hit how much of each sale it keepsBaxter Reports Second-Quarter 2026 Results
Quarterly YoY growth decelerated to 2.90% in Q1 2026, demonstrating potential variability across quarters.
From our researchWould hit how fast sales growBaxter Q1 2026 Form 10-Q
Fourth quarter GAAP operating margins were negative in 2024 (-15.80%) and 2025 (-24.51%) due to non-cash charges and restructuring.
From our researchWould hit how much of each sale it keepsBaxter 2025 Form 10-K
Is it a good business?
From 2016 to 2025 it earned between -9% and 15% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 6.6%; returns were above it in 4 of the 9 years.
From 2016 to 2025 it earned between -42% and 60% on its shareholders' equity, a median of 13%.
Over 10 years its operating margin ranged from 15¢ to 16¢ per sales dollar, a median of 10¢. Gross margin ran from 30¢ to 43¢.
Cost of capital 6.6%
The number of shares has held roughly steady over the past year.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $25.54. Our put its value between $7.01 and $50.56, with $27.71 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $7.01
This scenario assumes that hospital budget constraints and rising import duties slow annual sales growth to under two percent while ongoing restructuring costs keep business profits below historical double-digit levels.
Base case, $27.71
This scenario assumes that steady hospital demand for medical supplies and newly launched infusion systems maintains annual sales expansion around four percent while core business profitability gradually recovers toward historical norms.
Bull case, $50.56
This scenario assumes that strong adoption of digital hospital equipment and specialized injectable medications accelerates annual sales growth above five percent while manufacturing efficiency drives profitability back toward peak performance.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price and our value are close.Margin of safety: 8%
For Baxter International to be worth today's $25.54, sales would need to grow about 2.5% a year. We assume 3.6%. Over the last 5 years, sales shrank 1.4% a year.
Or, if sales grow 3.6% as we assume, the price works with a profit margin of 10.9% (we assume 11.5%).
Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.
Do you think sales can grow 2.5% a year?
Try your own numbersWe're moderately sure of this range: it scores 51 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $27.71 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average3.6%
- Operating margin11.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$27.71 8.5%


